Team:Evry/Seminar
From 2013.igem.org
Louis.ujeda (Talk | contribs) |
|||
Line 78: | Line 78: | ||
<img style="float:left;" src="https://static.igem.org/mediawiki/2013/9/91/Ga%C3%ABlNicolas.JPG" width="30%"/> | <img style="float:left;" src="https://static.igem.org/mediawiki/2013/9/91/Ga%C3%ABlNicolas.JPG" width="30%"/> | ||
- | <p> | + | <h3>Summary</h3> |
+ | <p>Iron is necessary to living beings but potentially toxic, that is why homeostasis is required. In a human body there are 4g to 5g of iron, that is about a rusted nail. Iron is present as Fe2+ and Fe3+; as Fe3+ it is insoluble and thus must be degraded in Fe2+, but as Fe2+ it becomes highly toxic because it is a strong oxidant. Much of iron is located in the red blood cells. This explains why we associate iron with oxygen transport, but many other reactions imply iron.<br/> | ||
+ | In the 1930's, an experiment showed that iron was not excreted by the body: iron remains stocked in the body. We absorb 1mg to 2mg of iron daily in order to compensate 1mg to 2 mg of iron lost daily through the death of cells. The production of red blood cells uses 20mg of iron daily, but these 20mg exclusively come from the recycling process of old red blood cells by macrophages.<br/> | ||
+ | Hepcidin is a hormone that makes the level of iron in the serum decrease. Hepcidin is thus to iron approximatively what insulin is to glucose. Its deficiency is implied in almost all the forms of hemochromatosis. This hormone has three sulphur bridges, that makes it very difficult to synthesise.</p> | ||
<p style="clear:both"> Question/Answer</p> | <p style="clear:both"> Question/Answer</p> |
Revision as of 11:54, 3 October 2013
Seminar on hemochromatosis the 18th of September
On the 18th of September, Evry iGEM team organized a seminar on hemochromatosis on iron related diseases. The aim of this seminar is to present the latest scientific advances on thoses diseases and futur treatments. We also take this opportunity to present synthetic biology and our project in iGEM competition to both scientists and patients.
Day's agenda
Start time | Speaker | Subject |
---|---|---|
10:00 | Gabriel Guillocheau | Opening speech |
10:15 | PHD-DR Gaël Nicolas | Iron homeostasis in mammals and its deregulation |
11:00 | PU-PH Pierre Brissot | Hemochromatosis: its diagnostic and its treatment |
11:45 | Break | |
12:00 | Docteur Marie-Paule Roth | Link between HFE, hepcidin and BMP6 |
12:45 | Lunch | |
14:15 | Result questionnaire with patients participation | |
15::00 | Nicolas Pollet | Microbiom studies |
15:45 | Break | |
16:00 | iGEM EVRY team | A bacterial treatment for hemochromatosis |
16:45 | Gabriel Guillocheau | Closing speech |
Report of the day
Gaël Nicolas: "Iron homeostasis in mammals and its deregulation"
Summary
Iron is necessary to living beings but potentially toxic, that is why homeostasis is required. In a human body there are 4g to 5g of iron, that is about a rusted nail. Iron is present as Fe2+ and Fe3+; as Fe3+ it is insoluble and thus must be degraded in Fe2+, but as Fe2+ it becomes highly toxic because it is a strong oxidant. Much of iron is located in the red blood cells. This explains why we associate iron with oxygen transport, but many other reactions imply iron.
In the 1930's, an experiment showed that iron was not excreted by the body: iron remains stocked in the body. We absorb 1mg to 2mg of iron daily in order to compensate 1mg to 2 mg of iron lost daily through the death of cells. The production of red blood cells uses 20mg of iron daily, but these 20mg exclusively come from the recycling process of old red blood cells by macrophages.
Hepcidin is a hormone that makes the level of iron in the serum decrease. Hepcidin is thus to iron approximatively what insulin is to glucose. Its deficiency is implied in almost all the forms of hemochromatosis. This hormone has three sulphur bridges, that makes it very difficult to synthesise.
Question/Answer
Q1: ....
A1: ...
Q2: ...
A2: ...
Pierre Brissot: "Hemochromatosis: its diagnostic and its treatment"
Here a little summary of the presentation
Question/Answer
Q1: ....
A1: ...
Q2: ...
A2: ...
Marie-Paule Roth: "Link between HFE, hepcidin and BMP6"
Here a little summary of the presentation
Question/Answer
Q1: ....
A1: ...
Q2: ...
A2: ...
Result questionnaire with patients participation
Here a little summary of the presentation
Question/Answer
Q1: ....
A1: ...
Q2: ...
A2: ...
Nicolas Pollet: "Microbiom studies"
Here a little summary of the presentation
Question/Answer
Q1: ....
A1: ...
Q2: ...
A2: ...
iGEM EVRY team: "A bacterial treatment for hemochromatosis"
Here a little summary of the presentation
Question/Answer
Q1: ....
A1: ...
Q2: ...
A2: ...
Ressenti de quelques intervenants